TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20973712
Drug: Placebo (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (fixed dose)
Study: 20973712
Drug: Aripiprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (both dosing regimens)
Study: 17052252
Drug: Doxazosin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (standard tablet)
Study: 17052252
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS (controlled release formulation)
Study: 17052252
Drug: Doxazosin, Tamsulosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin, Tamsulosin, Terazosin, Prazosin (α1-receptor antagonists)
Study: 16230074
Drug: Entecavir 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.1 mg daily
Study: 12123333
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot medroxyprogesterone acetate (MPA) 500 mg on days 1, 14, and 28
Study: 12123333
Drug: Oral megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral megestrol acetate 40 mg daily for 6 weeks
Study: 7836079
Drug: Radiotherapy 60
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy 60 Gy in 30 fractions in 6 weeks plus carboplatin 350 mg/m2 during weeks 1 and 5 (arm III)
Study: 7836079
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy 60 Gy in 30 fractions in 3 weeks plus carboplatin 350 mg/m2 during week 1 (arm IV)
Study: 2136775
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium bromide plus 4‐hourly fenoterol (group I, 50 patients)
Study: 2136775
Drug: 2‐hourly fenoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐hourly fenoterol (group II, 50 patients)
Study: 2136775
Drug: 4‐hourly fenoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐hourly fenoterol (group III, 45 patients)
Study: 26389597
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus memory support (CT + MS; n = 22)
Study: 26389597
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy as-usual (CT-as-usual; n = 20)
Study: 26389597
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus memory support (CT + MS)
Study: 26389597
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy as-usual (CT-as-usual)
Study: 24406614
Drug: Scopolamine transdermal
Normalized name: scopolamine Transdermal System
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine transdermal patch, dosage and duration not specified
Study: 23031065
Drug: Exercise prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescription (individually tailored home-based exercise prescriptions for 6 months)
Study: 20826257
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg/d; TEL, n = 25)
Study: 17519582
Drug: Tomato extract
Normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato extract (TE) 360 mg per day for 8 weeks
Study: 10434817
Drug: Patient-controlled i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled i.v. morphine (PCIM)
Study: 1977703
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine)
Study: 1977703
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (omeprazole)
Study: 82356
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g of oral zinc sulphate daily
Study: 24918475
Drug: 2.0 mL
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mL oral 24% sucrose (n=29)
Study: 19192993
Drug: Single-day famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-day famciclovir (1 g twice-daily)
Study: 19192993
Drug: 3-day valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day valacyclovir (500 mg twice-daily)
Study: 14716727
Drug: Success rates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Success rates in treatment and control groups
Study: 11471927
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg once daily in the evening (n = 15)
Study: 9035016
Drug: etodolac 150
Normalized name: etodolac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 150 mg bid
Study: 9035016
Drug: etodolac 500
Normalized name: etodolac 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 500 mg bid
Study: 31610100
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 75 mg
Study: 31610100
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 100 mg
Study: 26645271
Drug: Phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binder therapy taken with meals
Study: 26645271
Drug: Standard prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prescription of phosphate binders
Study: 24146510
Drug: General acteoside
Normalized name: Acteoside
DrugBank: Acteoside (DB12996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General acteoside of Rehmanniae leaves (two 200mg tablets, bid)
Study: 24146510
Drug: Piperazine ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperazine ferulate (four 50-mg tablets, bid)
Study: 21348543
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB treatment in vitiligo-melasma group
Study: 21348543
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB treatment in vitiligo group
Study: 18364505
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HT)
Study: 18364505
Drug: Best management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best management without hormones (Control)
Study: 8105717
Drug: Clonidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1 mg/kg propofol)
Study: 8105717
Drug: Clonidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1.5 mg/kg propofol)
Study: 8105717
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 mg/kg propofol)
Study: 8105717
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mg/kg propofol)
Study: 8105717
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 mg/kg propofol)
Study: 8105717
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mg/kg propofol)
Study: 29315132
Drug: Self-help cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help cognitive behavior therapy (SH-CBT)
Study: 29315132
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment waitlist control (NTWC)
Study: 27050189
Drug: IV metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metoprolol (2 × 5-mg bolus)
Study: 16105815
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg(‐1) iv
Study: 16105815
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg.kg(‐1) iv
Study: 14520853
Drug: Combined psychocorrection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychocorrection including neuroleptic trifluoperasine and psychorelaxation therapy
Study: 2572248
Drug: Ranitidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 80 mg
Study: 30554749
Drug: IYCF (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IYCF (20 g of a small‐quantity lipid‐based nutrient supplement per day from age 6 to 18 months plus complementary feeding counselling)
Study: 17554644
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (group A, no pharmacotherapy)
Study: 17554644
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (group B, with pharmacotherapy)
Study: 9919837
Drug: Uncoated theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated theophylline tablet (200 mg, 300 mg dose 5 mg/kg approx) administered orally after 12 hours overnight fasting
Study: 3299681
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) oral gold
Study: 18212313
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) and androgen suppression therapy (AST) combined
Study: 3518911
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy in a randomized trial
Study: 24990113
Drug: Formulations (powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations (powder in capsule [PIC], immediate-release tablet [IRT], commercial formulated capsule [FC])
Study: 22384983
Drug: Moisturizing lotion
Normalized name: MOISTURIZING LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing lotion (Cetaphil®) + adapalene gel 0.1%
Study: 22384983
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1% only
Study: 20864883
Drug: MS‐sNT (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS‐sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Study: 20864883
Drug: KADIAN® (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: KADIAN® (morphine sulfate extended release capsules)
Study: 2883837
Drug: EA +
Normalized name: Echinacea + bioflavonoid + vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA + naloxone (0.8 mg IM)
Study: 29428844
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment; n = 17)
Study: 18678119
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3 units (600 ml) of fresh frozen plasma (FFP) over 90 minutes
Study: 18678119
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isotonic saline over 90 minutes
Study: 12133885
Drug: Dynamic colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic colostrum (20 g daily for 2 weeks)
Study: 12133885
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g maltodextrin daily for 2 weeks)
Study: 10467919
Drug: Antidepressants prescribed
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants prescribed to women with non-cancer pain
Study: 10467919
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment history and current analgesic use in non-cancer pain patients
Study: 10467919
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment variables in cancer pain patients
Study: 2212391
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C restriction with a daily intake of 25 mg/day (after 3 weeks of low intake)
Study: 2212391
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with the same diet supplemented with twice the RDA for all vitamins
Study: 627883
Drug: Methadone 40
Normalized name: methadone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 40 mg/day
Study: 627883
Drug: Methadone 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 80 mg/day
Study: 627883
Drug: Heroin (0.214
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (0.214 mg/kg)
Study: 25162212
Drug: IL-2 receptor
Normalized name: Il-2 receptor alpha chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 receptor antagonists (IL-2RAs)
Study: 11718271
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: DTX (80 mg/m2) followed by VNR (25 mg/m2)
Study: 11718271
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: VNR (25 mg/m2) followed by DTX (80 mg/m2)
Study: 9850014
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CEF: cyclophosphamide 500 mg/m2, epirubicin 60 mg/m2, fluorouracil 500 mg/m2)
Study: 9850014
Drug: Single-agent epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent epirubicin (20 mg/m2) followed by single-agent mitomycin (8 mg/m2)
Study: 9850014
Drug: Single-agent mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent mitomycin (8 mg/m2)
Study: 9850014
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CEF) followed by mitomycin and vinblastine (MV)
Study: 9850014
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CEF)
Study: 8014492
Drug: ethambutol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethambutol (15 mg/kg)
Study: 8014492
Drug: clofazimine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: clofazimine (200 mg)
Study: 8014492
Drug: rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampin (600 mg)
Study: 2509917
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (2 million units) subcutaneously three times weekly for six months
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) 10 mg single dose
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) 25 mg single dose
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) 50 mg single dose
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) once-daily 10 mg for 21 days
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) once-daily 25 mg for 21 days
Study: 29125703
Drug: Mavatrep (JNJ-39439335)
Normalized name: Mavatrep
DrugBank: Mavatrep (DB12875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavatrep (JNJ-39439335) once-daily 50 mg for 21 days
Study: 16226044
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment in localized prostate cancer (T1‐2 N0) with poor prognostic factors: Gleason score 8‐10, PSA>20 ng/ml
Study: 7793217
Drug: ketobemidone 5
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketobemidone 5 mg
Study: 1778085
Drug: Chlorthalidone plus
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone plus Triamterene (25 mg + 50 mg)
Study: 7249547
Drug: DL-propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-propranolol (0.1 mg/kg)
Study: 7249547
Drug: D-propranolol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-propranolol (1.0 mg/kg)
Study: 26673802
Drug: Palonosetron 0.5
Normalized name: palonosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.5 mcg kg⁻¹
Study: 26673802
Drug: Palonosetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 1.0 mcg kg⁻¹
Study: 26673802
Drug: Palonosetron 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 1.5 mcg kg⁻¹
Study: 20004526
Drug: Dose outside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose outside the prostate (68-78 Gy)
Study: 17425493
Drug: Antiplatelet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet and antithrombotic agents
Study: 15657070
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone 20 mg and eight sessions of standardized physiotherapy
Study: 15657070
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone 20 mg alone
Study: 15657070
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection and eight sessions of standardized physiotherapy
Study: 15657070
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection alone
Study: 10592533
Drug: Amtolmetina guacyl
Normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetina guacyl (Eufans) 600 mg once daily for 14 consecutive days per month for 2 months (P, n = 10; PV, n = 8; PVE, n = 7)
Study: 10592533
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (matched-control, n = 6 for each category)
Study: 10592533
Drug: Amtolmetina guacyl
Normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetina guacyl treatment (after first course T1)
Study: 10592533
Drug: Amtolmetina guacyl
Normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetina guacyl treatment (after second course T2)
Study: 10592533
Drug: Amtolmetina guacyl
Normalized name: dextromethorphan hydrobromide / guaiacolsulfonate Oral Solution [Guacol DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetina guacyl treatment (T2)
Study: 8708166
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (NS) 100 cc with Unweighted tube (UNW)
Study: 8708166
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (NS) 100 cc with Weighted tube (WEI)
Study: 8708166
Drug: Erythromycin (EMY)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin (EMY) 200 mg with Weighted tube (WEI)
Study: 8708166
Drug: Metoclopramide (MET)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MET) 10 mg with Weighted tube (WEI)
Study: 31747009
Drug: Depatux‐M 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatux‐M 1.25 mg/kg every 2 weeks intravenously
Study: 31747009
Drug: Depatux‐M monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatux‐M monotherapy
Study: 31747009
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Depatux‐M with temozolomide
Study: 26507718
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (surgery using tension band wiring or plate fixation)
Study: 26507718
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (early range of motion as tolerated)
Study: 17696259
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg/d
Study: 17696259
Drug: Lamivudine (LVD)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LVD) 100 mg/d
Study: 17696259
Drug: Lamivudine (LVD)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LVD) switched to Entecavir (ETV) 1.0 mg/d
Study: 15145968
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg) 1-minute infusion
Study: 15145968
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg) 1-hour infusion
Study: 15145968
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg) 3-hour infusion
Study: 7491044
Drug: Streptokinase (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.5 MU intravenous infusion for 1 hour)
Study: 10629348
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus aspirin
Study: 7491044
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day for 10 days)
Study: 7020563
Drug: Sorghum beer
Normalized name: Sorghum
DrugBank: Sorghum (DB17914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorghum beer (2 litres, carbohydrate content approximately 5%, alcohol concentration 2.24 g/dl-2.8% v/v)
Study: 7020563
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (2 litres providing a similar carbohydrate load)
Study: 31081522
Drug: Half-dose ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose ticagrelor (90 mg LD, then 45 mg twice daily)
Study: 31081522
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel (150 mg once daily)
Study: 27455854
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.2 g/kg bw
Study: 27455854
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIg) IgPro20 at 0.4 g/kg bw
Study: 10589403
Drug: Butoconazole 1-BSR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butoconazole 1-BSR (single dose)